دورية أكاديمية
Cost-effectiveness of clinical breast examination screening programme among HER2-positive breast cancer patients: a modelling study.
| العنوان: | Cost-effectiveness of clinical breast examination screening programme among HER2-positive breast cancer patients: a modelling study. |
|---|---|
| المؤلفون: | Ngan TT; Centre for Public Health, Queen's University Belfast, Belfast, UK. n.t.tran@qub.ac.uk.; Centre for Population Health Sciences, Hanoi University of Public Health, Hanoi, Vietnam. n.t.tran@qub.ac.uk., Browne S; Roche Products Ireland Limited, Dublin, Ireland., Goodwin M; Roche Products Ireland Limited, Dublin, Ireland., Van Minh H; Centre for Population Health Sciences, Hanoi University of Public Health, Hanoi, Vietnam., Donnelly M; Centre for Public Health, Queen's University Belfast, Belfast, UK., O'Neill C; Centre for Public Health, Queen's University Belfast, Belfast, UK. |
| المصدر: | Breast cancer (Tokyo, Japan) [Breast Cancer] 2023 Jan; Vol. 30 (1), pp. 68-76. Date of Electronic Publication: 2022 Aug 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Maruzen Co Country of Publication: Japan NLM ID: 100888201 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-4233 (Electronic) Linking ISSN: 13406868 NLM ISO Abbreviation: Breast Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Tokyo : Maruzen Co., |
| مواضيع طبية MeSH: | Breast Neoplasms*/pathology, Humans ; Female ; Cost-Benefit Analysis ; Early Detection of Cancer ; Mammography ; Mass Screening |
| مستخلص: | Purpose: For many low- and middle-income countries (LMICs), breast cancer (BC) screening based on mammography is not a viable option. Clinical breast examination (CBE) may represent a pragmatic and cost-effective alternative. This paper examines the cost-effectiveness of CBE screening programme among a patient group for whom its cost-effectiveness is likely to be least evident (HER2-positive patients) and discuss the wider implications for BC screening in LMICs. Methods: A Markov model was used to examine clinical and economic outcomes over a life-time horizon from the patient, public payer, and healthcare sector perspective. HER2-positive patients entered the model at either disease-free survival or metastatic BC state. The downstaging effect of CBE determined the starting probabilities in the no-screening and screening scenarios. The model used a monthly cycle length, with half-cycle correction. Costs and outcomes were discounted at 1.5% annually. Results: Compared with no-screening, the cost-effectiveness ratio (ICER) per quality-adjusted life-year gained for the CBE screening programme was $1801, $2381, and $4179 from three mentioned perspectives, respectively. The finding of cost-effectiveness remained robust to a range of sensitivity analyses. The parameters to which ICERs are most sensitive are average age of cohorts, reduction in proportion of metastatic patients at diagnosis, cost of CBE, and BC detection rate of the programme. Conclusion: For HER2-positive patients and compared with no-screening, CBE screening programme in Vietnam is cost-effective from all investigated perspectives. CBE is a 'good value' intervention and should be considered for implementation throughout Vietnam as well as in LMICs where mammography is not feasible. (© 2022. The Author(s).) |
| References: | Glob Health Action. 2013 Jan 17;6:1-9. (PMID: 23336619) BMC Public Health. 2022 Jan 10;22(1):61. (PMID: 35012517) Value Health Reg Issues. 2013 May;2(1):21-28. (PMID: 29702847) Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):977-85. (PMID: 25832690) Curr Oncol. 2020 Dec;27(6):e578-e589. (PMID: 33380873) Trop Med Int Health. 2012 Aug;17(8):1031-43. (PMID: 22809238) PLoS One. 2013 Dec 10;8(12):e82575. (PMID: 24349314) Cancer. 1991 Apr 15;67(8):2021-9. (PMID: 1900734) Asian Pac J Cancer Prev. 2013;14(7):4141-9. (PMID: 23991967) Bull World Health Organ. 2015 Feb 1;93(2):118-24. (PMID: 25883405) Cancer Med. 2019 Dec;8(18):7846-7858. (PMID: 31568702) Qual Life Res. 2022 Mar;31(3):777-787. (PMID: 34541610) Lancet. 2017 Mar 25;389(10075):1195-1205. (PMID: 28215665) Value Health. 2016 Sep - Oct;19(6):903-908. (PMID: 27712720) J Natl Cancer Inst. 2008 Sep 17;100(18):1290-300. (PMID: 18780864) Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457. (PMID: 28223433) Cancer Sci. 2006 Nov;97(11):1242-7. (PMID: 16918992) |
| فهرسة مساهمة: | Keywords: Breast cancer; Clinical breast examination; Cost-effectiveness analysis; Health economics; Low- and middle-income countries |
| تواريخ الأحداث: | Date Created: 20220826 Date Completed: 20230106 Latest Revision: 20230111 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/s12282-022-01398-2 |
| PMID: | 36028594 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1880-4233 |
|---|---|
| DOI: | 10.1007/s12282-022-01398-2 |